Other languages Kronos Bio, Inc.

Equities

KRON

US50107A1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.98 ^USD	+2.08%		-4.85%	-21.60%

Mar. 21	Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M	MT
Mar. 21	Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study	Mar. 07
Kronos Bio Plans to Reduction in Force	Mar. 07
Kronos Bio Announces Management Shakeup, 3 Top Managers to Step Down in February	Jan. 25
Kronos Bio, Inc. Announces Executive Changes	Jan. 25
Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate	Dec. 18
Kronos Bio Insider Bought Shares Worth $1,470,395, According to a Recent SEC Filing	Nov. 17
Kronos Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Kronos Bio to Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 Kb-0742 Study At the Connective Tissue Oncology Society Annual Meeting	23-10-27
Kronos Bio, Inc. Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC	23-10-13
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer	23-09-18
Kronos Bio, Inc. Appoints Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer	23-09-18
Kronos Bio Finance Chief Yasir Al-Wakeel Resigning	23-08-17
Kronos Bio Announces Resignation of Yasir Al-Wakeel as Head of Corporate Development, Effective from September 15, 2023	23-08-17
Kronos Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Kronos Bio, Inc. Appoints Marc Besman as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance	23-06-06
Kronos Bio, Inc. Appoints Katherine Vega Stultz as Member of the Audit Committee and of the Compensation Committee of the Board	23-05-30
Kronos Bio, Inc. Appoints Roger Dansey as Member of the Nominating and Corporate Governance Committee of the Board	23-05-30
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kronos Bio, Inc.

Equities

KRON

US50107A1043

Other languages

Filters